First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...

IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12 IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian ...

IMNN-001, in patients with advanced ovarian cancer. IMNN-001 is a DNA immunotherapeutic drug that consists of an interleukin (IL)-12 expressing plasmid that allows for the durable, local ...

IMUNON, Inc. has announced the initiation of a Phase 3 pivotal trial, OVATION 3, for its DNA-mediated immunotherapy candidate, IMNN-001, targeting newly diagnosed advanced ovarian cancer.

IMNN-001, an immunotherapy for advanced ovarian cancer, shows promising survival data, with a Phase 3 trial set for 2025. IMUNON, Inc. reported that its DNA-mediated immunotherapy, IMNN-001 ...

"2024 was a pivotal year for IMUNON. We reported robust and unprecedented data from our Phase 2 OVATION 2 Study, demonstrating that IMNN-001 is the first immunotherapy to consistently show clinical ...

“The Phase 2 OVATION 2 study data are highly encouraging, demonstrating that IMNN-001 is the first immunotherapy to achieve a clinically effective response in ovarian cancer, including benefits ...